

For Immediate Release

Net Revenue up 33%, Net Profit up 50%

Vadodara July 27th, 2018

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ending 30th June 2018.

Financial Highlights

- Net Sales for the quarter up 33% to Rs 863 crores against Rs 648 crores last year.
- Net Profit up 50% to Rs 98 crores from Rs 65 crores last year.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "The robust performance in the quarter is attributed to growth across territories. This was led by India Formulation business which was impacted by GST transition last year."

Operational Highlights for the quarter

International Business

- International Formulation business grew 25% to Rs 352 crores.
- EIR Received from the US FDA for Panpharm Formulation Facility.
- EIR Received from the US FDA for API III at Karakhadi.
- 3 ANDA approvals received during the quarter, Cumulative ANDA approvals at 73 including 9 tentative approval.
- 3 ANDA filings during the quarter, Cumulative ANDA filings at 135.
- R&D spend at Rs 122 Crores, 14% of Sales.

India Formulations Business

- India formulations business grew 40% to Rs 331 crores as against Rs 236 crores last year.



ALEMBIC PHARMACEUTICALS LIMITED

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q1 FY19	Q1 FY18
Formulation		
International	352	282
India	331	236
API	180	130
Total	863	648

The Profit break-up is as under:

(Rs in Crores)

Particulars	Q1 FY19	Q1 FY18
EBITDA Pre R&D	267	195
<i>EBITDA Pre R&D %</i>	31%	30%
EBITDA Post R&D	151	105
<i>EBITDA Post R&D %</i>	18%	16%
Profit Before Tax	122	79
Net Profit after Tax	98	65

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
 website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters: ALEM.NS) (bloomberg: ALPM) (nse: APLLTD) (bse: 533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 – 306 11681	Phone: +91 265 – 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123